Corcept is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of severe and orphan metabolic and psychiatric disorders caused by irregularly high levels of the steroid hormone cortisol. Corcept’s lead product, Korlym, is FDA approved for the treatment of Cushing’s syndrome and being developed for psychotic depression.
- Sector: Healthcare
- Status: Public (NASDAQ: CORT)
- Geographic Market: U.S.
- Investment Year: 2011
- Investment Team: Abhijeet Lele, Ashley Friedman, Yuriy Prilutskiy
Visit the company’s website.